Moderna, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
Moderna to Present at Upcoming Conference in June 2026
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Moderna, Merck cancer combo cuts melanoma spread risk at five years
US FDA to hold expert committee meeting to review Moderna's flu vaccine
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Moderna Recognized by TIME as One of the World's Most Impactful Companies
Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Moderna's AI Could Get a Hantavirus Vaccine Here Faster
Hantavirus outbreak: these 3 stocks are poised to rip higher
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.